What's Keeping CAR T-Cell Therapies From the Outpatient Setting?

Darcy Lewis
Published: Wednesday, Mar 13, 2019
Andre Goy, MD

Andre Goy, MD
Chimeric antigen receptor (CAR) T-cell therapies have been commercially available for less than 2 years. In that short time, they have fundamentally improved the prognosis for many patients with lymphoma and leukemia. Although these therapies were initially conceived of and developed as inpatient therapies, interest is growing in extending CAR T-cell therapies to the outpatient setting.

 

Table. Oncologists' Perceptions About Toxicity and Management of CAR T-cell Therapy

Table.  Oncologists' Perceptions About Toxicity and Management of CAR T-cell Therapy

AE indicates adverse effects; CAR, chimeric antigen receptor.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x